Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy

The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven co...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2012-08, Vol.32 (8), p.3581-3586
Main Authors: YOON, Yongsik, CHANWOOKKIM, SEONAEROH, HYUNGCHO, Dong, GYUPYOKIM, YONG SANG HONG, TAE WON KIM, MOON BO KIM, JIN CHEON KIM
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Colorectal Neoplasms - drug therapy
Drug Screening Assays, Antitumor
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Middle Aged
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumor Cells, Cultured
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 3586
container_issue 8
container_start_page 3581
container_title Anticancer research
container_volume 32
creator YOON, Yongsik
CHANWOOKKIM
SEONAEROH
HYUNGCHO, Dong
GYUPYOKIM
YONG SANG HONG
TAE WON KIM
MOON BO KIM
JIN CHEON KIM
description The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1030349699</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1030349699</sourcerecordid><originalsourceid>FETCH-LOGICAL-p241t-98e683cf650cb5024b9f399038f74c482deccbbd98156578980b1c755d7e22e23</originalsourceid><addsrcrecordid>eNpF0MtKxDAYBeAgijOOvoJkI7gppLk1WQ71CgOCjOuSpH-dSNrUpF307R1wxNXZfBw45wyty0qXRSUYOUdrQgUpKkLECl3l_EWIlFqxS7SiVHGmuV6j_XYcg3fG-uCnBccOv_g8RTeHaU6AH9L8id8hj3HIgLc5myVjP-A6hpjATSbg2gwOEq4P0MfpAMmMyzW66EzIcHPKDfp4etzXL8Xu7fm13u6KkfJyKrQCqZjrpCDOCkK51R3TmjDVVdxxRVtwztpWq1JIUSmtiC1dJURbAaVA2Qbd__aOKX7PkKem99lBCGaAOOemJIwwrqXWR3p7orPtoW3G5HuTlubviSO4OwGTnQldOs7y-d_JUhBGFfsBsZhn1A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1030349699</pqid></control><display><type>article</type><title>Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>YOON, Yongsik ; CHANWOOKKIM ; SEONAEROH ; HYUNGCHO, Dong ; GYUPYOKIM ; YONG SANG HONG ; TAE WON KIM ; MOON BO KIM ; JIN CHEON KIM</creator><creatorcontrib>YOON, Yongsik ; CHANWOOKKIM ; SEONAEROH ; HYUNGCHO, Dong ; GYUPYOKIM ; YONG SANG HONG ; TAE WON KIM ; MOON BO KIM ; JIN CHEON KIM</creatorcontrib><description>The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p&lt;0.001). Out of 86 evaluated chemotherapeutic regimes, the correlation rate of HDRA to the clinical effect of chemotherapy was calculated to be 66.3% (57/86), with a 72.7% (40/55) sensitivity and a 54.7% (17/31) specificity. HDRA might be a feasible and useful technique for predicting therapy efficacy and selecting the appropriate anticancer regime for individual patients, notwithstanding its low accuracy.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 22843949</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Colorectal Neoplasms - drug therapy ; Drug Screening Assays, Antitumor ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Male ; Medical sciences ; Middle Aged ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumor Cells, Cultured ; Tumors</subject><ispartof>Anticancer research, 2012-08, Vol.32 (8), p.3581-3586</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26150328$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22843949$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YOON, Yongsik</creatorcontrib><creatorcontrib>CHANWOOKKIM</creatorcontrib><creatorcontrib>SEONAEROH</creatorcontrib><creatorcontrib>HYUNGCHO, Dong</creatorcontrib><creatorcontrib>GYUPYOKIM</creatorcontrib><creatorcontrib>YONG SANG HONG</creatorcontrib><creatorcontrib>TAE WON KIM</creatorcontrib><creatorcontrib>MOON BO KIM</creatorcontrib><creatorcontrib>JIN CHEON KIM</creatorcontrib><title>Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p&lt;0.001). Out of 86 evaluated chemotherapeutic regimes, the correlation rate of HDRA to the clinical effect of chemotherapy was calculated to be 66.3% (57/86), with a 72.7% (40/55) sensitivity and a 54.7% (17/31) specificity. HDRA might be a feasible and useful technique for predicting therapy efficacy and selecting the appropriate anticancer regime for individual patients, notwithstanding its low accuracy.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNpF0MtKxDAYBeAgijOOvoJkI7gppLk1WQ71CgOCjOuSpH-dSNrUpF307R1wxNXZfBw45wyty0qXRSUYOUdrQgUpKkLECl3l_EWIlFqxS7SiVHGmuV6j_XYcg3fG-uCnBccOv_g8RTeHaU6AH9L8id8hj3HIgLc5myVjP-A6hpjATSbg2gwOEq4P0MfpAMmMyzW66EzIcHPKDfp4etzXL8Xu7fm13u6KkfJyKrQCqZjrpCDOCkK51R3TmjDVVdxxRVtwztpWq1JIUSmtiC1dJURbAaVA2Qbd__aOKX7PkKem99lBCGaAOOemJIwwrqXWR3p7orPtoW3G5HuTlubviSO4OwGTnQldOs7y-d_JUhBGFfsBsZhn1A</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>YOON, Yongsik</creator><creator>CHANWOOKKIM</creator><creator>SEONAEROH</creator><creator>HYUNGCHO, Dong</creator><creator>GYUPYOKIM</creator><creator>YONG SANG HONG</creator><creator>TAE WON KIM</creator><creator>MOON BO KIM</creator><creator>JIN CHEON KIM</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20120801</creationdate><title>Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy</title><author>YOON, Yongsik ; CHANWOOKKIM ; SEONAEROH ; HYUNGCHO, Dong ; GYUPYOKIM ; YONG SANG HONG ; TAE WON KIM ; MOON BO KIM ; JIN CHEON KIM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p241t-98e683cf650cb5024b9f399038f74c482deccbbd98156578980b1c755d7e22e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YOON, Yongsik</creatorcontrib><creatorcontrib>CHANWOOKKIM</creatorcontrib><creatorcontrib>SEONAEROH</creatorcontrib><creatorcontrib>HYUNGCHO, Dong</creatorcontrib><creatorcontrib>GYUPYOKIM</creatorcontrib><creatorcontrib>YONG SANG HONG</creatorcontrib><creatorcontrib>TAE WON KIM</creatorcontrib><creatorcontrib>MOON BO KIM</creatorcontrib><creatorcontrib>JIN CHEON KIM</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YOON, Yongsik</au><au>CHANWOOKKIM</au><au>SEONAEROH</au><au>HYUNGCHO, Dong</au><au>GYUPYOKIM</au><au>YONG SANG HONG</au><au>TAE WON KIM</au><au>MOON BO KIM</au><au>JIN CHEON KIM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>32</volume><issue>8</issue><spage>3581</spage><epage>3586</epage><pages>3581-3586</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p&lt;0.001). Out of 86 evaluated chemotherapeutic regimes, the correlation rate of HDRA to the clinical effect of chemotherapy was calculated to be 66.3% (57/86), with a 72.7% (40/55) sensitivity and a 54.7% (17/31) specificity. HDRA might be a feasible and useful technique for predicting therapy efficacy and selecting the appropriate anticancer regime for individual patients, notwithstanding its low accuracy.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>22843949</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0250-7005
ispartof Anticancer research, 2012-08, Vol.32 (8), p.3581-3586
issn 0250-7005
1791-7530
language eng
recordid cdi_proquest_miscellaneous_1030349699
source EZB-FREE-00999 freely available EZB journals
subjects Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Colorectal Neoplasms - drug therapy
Drug Screening Assays, Antitumor
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Middle Aged
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumor Cells, Cultured
Tumors
title Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A44%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Applicability%20of%20Histoculture%20Drug%20Response%20Assays%20in%20Colorectal%20Cancer%20Chemotherapy&rft.jtitle=Anticancer%20research&rft.au=YOON,%20Yongsik&rft.date=2012-08-01&rft.volume=32&rft.issue=8&rft.spage=3581&rft.epage=3586&rft.pages=3581-3586&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1030349699%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p241t-98e683cf650cb5024b9f399038f74c482deccbbd98156578980b1c755d7e22e23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1030349699&rft_id=info:pmid/22843949&rfr_iscdi=true